Have a feature idea you'd love to see implemented?
Let us know!
APRE Aprea Therapeutics Inc
Price (delayed)
$4.25
Market cap
$23.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.03
Enterprise value
-$5.65M
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor
Highlights
Aprea Therapeutics's revenue has increased by 32% from the previous quarter
The company's gross profit rose by 32% QoQ
APRE's EPS has dropped by 128% year-on-year but it is up by 9% since the previous quarter
The quick ratio has grown by 32% YoY but it has contracted by 15% from the previous quarter
Key stats
What are the main financial stats of APRE
Market
Valuations
Earnings
Shares outstanding
5.43M
Market cap
$23.09M
Enterprise value
-$5.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
19.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.43
Revenue
$1.28M
EBIT
-$14.23M
EBITDA
-$14.21M
Free cash flow
-$13.58M
Per share
Balance sheet
Liquidity
EPS
-$3.03
Free cash flow per share
-$2.29
Book value per share
$4.71
Revenue per share
$0.21
TBVPS
$5.05
Total assets
$29.96M
Total liabilities
$4.41M
Debt
$0
Equity
$25.56M
Working capital
$26.47M
Debt to equity
0
Current ratio
9.55
Quick ratio
9.29
Net debt/EBITDA
2.02
Margins
Efficiency
Dividend
EBITDA margin
-1,113.7%
Gross margin
100%
Net margin
-1,013.4%
Operating margin
-1,112.7%
Return on assets
-46.3%
Return on equity
-56.4%
Return on invested capital
N/A
Return on capital employed
-52.9%
Return on sales
-1,115.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APRE stock price
How has the Aprea Therapeutics stock price performed over time
Intraday
-0.7%
1 week
1.67%
1 month
54.55%
1 year
20.06%
YTD
-9.57%
QTD
54.55%
Financial performance
How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$1.28M
Gross profit
$1.28M
Operating income
-$14.19M
Net income
-$12.93M
Gross margin
100%
Net margin
-1,013.4%
The company's operating margin has surged by 82% YoY and by 23% QoQ
The net margin has surged by 82% year-on-year and by 23% since the previous quarter
Aprea Therapeutics's revenue has increased by 32% from the previous quarter
The company's gross profit rose by 32% QoQ
Growth
What is Aprea Therapeutics's growth rate over time
Valuation
What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.9
P/S
19.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.43
APRE's EPS has dropped by 128% year-on-year but it is up by 9% since the previous quarter
APRE's P/B is 63% below its 5-year quarterly average of 2.4 and 11% below its last 4 quarters average of 1.0
The equity has contracted by 12% from the previous quarter but it has grown by 9% YoY
Aprea Therapeutics's revenue has increased by 32% from the previous quarter
APRE's P/S is 26% below its last 4 quarters average of 26.1
Efficiency
How efficient is Aprea Therapeutics business performance
APRE's return on sales has surged by 82% year-on-year and by 23% since the previous quarter
Aprea Therapeutics's ROA has decreased by 2.2% YoY
The company's return on equity fell by 2.2% YoY
Dividends
What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APRE.
Financial health
How did Aprea Therapeutics financials performed over time
The quick ratio has grown by 32% YoY but it has contracted by 15% from the previous quarter
The current ratio has increased by 32% YoY but it has decreased by 14% from the previous quarter
The debt is 100% smaller than the equity
The equity has contracted by 12% from the previous quarter but it has grown by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.